Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831

Diabetes Care- United States

doi 10.2337/dc18-er03a

Full Text

Abstract

Available in

Date

Authors

Publisher

American Diabetes Association

Related search

Cardiovascular Outcome Trials of Diabetes Drugs: Lessons Learned

Journal of Clinical Investigation
Medicine
2018English

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Lessons From a Cardiovascular Outcome Trial With Liraglutide in Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2017English

Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Cardiovascular Outcome Trials in Diabetes: What Have We Learnt?

Trends in Urology & Men's Health
2018English

Risk of Major Cardiovascular Events in Patients With Type 2 Diabetes With and Without Prior Cardiovascular Events: Results From the Leader Trial

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Type 2 Diabetes and Cardiovascular Risk Factors

Current Medical Research and Opinion
Medicine
2011English

Consistent Cardiovascular (CV) Benefit of Empagliflozin Over the Spectrum of CV Risk Factor Control in EMPA-REG OUTCOME

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy